Discovery of Phenylpropanoic Acid Derivatives Containing Polar Functionalities as Potent and Orally Bioavailable G Protein-Coupled Receptor 40 Agonists for the Treatment of Type 2 Diabetes
Authors:
- 11 April 2012
- journal article
- research article
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 55 (8) , 3756-3776
Abstract
As part of a program to identify potent GPR40 agonists with drug-like properties suitable for clinical development, the incorporation of polar substituents was explored with the intention of decreasing the lipophilicity of our recently disclosed phenylpropanoic acid derivative 1. This incorporation would allow us to mitigate the cytotoxicity issues observed with compound 1 and enable us to move away from the multifunctional free fatty acid-like structure. Substitutions on the 2′,6′-dimethylbiphenyl ring were initially undertaken, which revealed the feasibility of introducing polar functionalities at the biphenyl 4′-position. Further optimization of this position and the linker led to the discovery of several 4′-alkoxybiphenyl derivatives, which showed potent GPR40 agonist activities with the best balance in terms of improved cytotoxicity profiles and favorable pharmacokinetic properties. Among them, 3-{2-fluoro-4-[({4′-[(4-hydroxy-1,1-dioxidotetrahydro-2H-thiopyran-4-yl)methoxy]-2′,6′-dimethylbiphenyl-3-yl}methyl)amino]phenyl}propanoic acid (35) exhibited a robust plasma glucose-lowering effect and insulinotropic action during an oral glucose tolerance test in rats with impaired glucose tolerance.Keywords
This publication has 57 references indexed in Scilit:
- The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetesThe Lancet, 2006
- Sulfonylurea Induced β-Cell Apoptosis in Cultured Human IsletsThe Journal of Clinical Endocrinology & Metabolism, 2005
- Effects of prolonged in vitro exposure to sulphonylureas on the function and survival of human isletsJournal of Diabetes and its Complications, 2005
- The Role of Sulphonylureas in the Management of Type 2 Diabetes MellitusDrugs, 2004
- The Genetic Basis of Type 2 Diabetes Mellitus: Impaired Insulin Secretion versus Impaired Insulin SensitivityEndocrine Reviews, 1998
- Effect of a New Hypoglycemic Agent, A-4166 ((-)-N-(trans-4-Isopropylcyclohexanecarbonyl)-D-phenylalanine), on Postprandial Blood Glucose Excursion: Comparison with Voglibose and Glibenclamide.Biological and Pharmaceutical Bulletin, 1997
- Insulin Resistance or Insulin Deficiency: Which Is the Primary Cause of NIDDM?Diabetes, 1994
- Insulin resistance and insulin deficiency in the pathogenesis of Type 2 (non-insulin-dependent) diabetes mellitus: errors of metabolism or of methods?Diabetologia, 1993
- Sulphonylureas and hypoglycaemiaBMJ, 1988
- Glibenclamide-associated hypoglycaemia: A report on 57 casesDiabetologia, 1983